Legislature(2017 - 2018)BUTROVICH 205
02/10/2017 01:30 PM Senate HEALTH & SOCIAL SERVICES
Note: the audio and video recordings are distinct records and are obtained from different sources. As such there may be key differences between the two. The audio recordings are captured by our records offices as the official record of the meeting and will have more accurate timestamps. Use the icons to switch between them.
Audio | Topic |
---|---|
Start | |
SB20 | |
SB32 | |
Adjourn |
* first hearing in first committee of referral
+ teleconferenced
= bill was previously heard/scheduled
+ teleconferenced
= bill was previously heard/scheduled
*+ | SB 32 | TELECONFERENCED | |
+ | TELECONFERENCED | ||
+= | SB 20 | TELECONFERENCED | |
SB 20-LIST U-47700 AS A CONTROLLED SUBSTANCE 1:30:48 PM CHAIR WILSON announced the consideration of SB 20. He noted the proposed committee substitute (CS), 30-LS0319\D. 1:31:19 PM SENATOR VON IMHOF moved to adopt the work draft CS for SB 20, version 30-LS0319\D, as the working document. CHAIR WILSON asked if there was an objection to adopting the CS. SENATOR VON IMHOF objected for discussion purposes. 1:32:07 PM SENATOR MICCICHE joined the committee meeting. 1:32:16 PM CHRISTINE MARASIGAN, Staff, Senator Kevin Meyer, Alaska State Legislature, Juneau, Alaska, explained the CS for SB 20 as follows: Page 4, line 30: Misspelling corrected, adding a "z" in the word that was brought up by Dr. Butler. Page 4, line 31: There's a new Section 2, this new section continues on page 5, lines 1-6 which basically inserts the language to have tramadol be Schedule IVA controlled substance thus bringing Alaska statute in line with what has already happened on the national level of tramadol. CHAIR WILSON asked if the objection to the CS is maintained. 1:33:05 PM SENATOR VON IMHOF removed her objection. CHAIR WILSON announced that without objection, the CS for SB 20, version D, is adopted by the committee. SENATOR MICCICHE asked to comment prior to moving the bill out of committee. He stated that the things that he has been looking at to try and present more of a catch-all moving forward needs more work. He asserted that the bill definitely improves the situation and he is very supportive. He said he will be getting with those that are experts, including [Senator Giessel], to work on recommendations going forward. CHAIR WILSON stated that he appreciated Senator Micciche's comment and noted that all committee members would like a more in-depth solution to the matter that plagues the state's communities. SENATOR KEVIN MEYER, Alaska State Legislature, Juneau, Alaska, Sponsor of SB 20. Commented as follows: I certainly agree with Senator Micciche and I think we had a really good discussion on this topic and how we need to come up with a system so that we can react quicker, faster, be a little more nimble than waiting for us to come into session and go through the process of passing a law; although, we are creating a new law with a pretty severe crime. So, I think it does deserve a deliberative process, but I would agree I think Senator Giessel and her opioid task force might be a good place to start the discussion or this committee and we are certainly very supportive and want to help in any way we can, but at least what this will do now is get this particular bill or this particular drug which we know is currently a serious problem, unlawful and against the law, so that the police force can now start implementing appropriate penalties. CHAIR WILSON disclosed that the plan in future weeks is to have the Statewide Drug Enforcement Unit and the Alaska Opioid Policy Task Force present options before the committee to solve the problem that SB 20 addresses. SENATOR MEYER thanked Chair Wilson. CHAIR WILSON asked if there is any objection to Senator von Imhof's motion to move SB 20. 1:35:29 PM SENATOR VON IMHOF moved to report the CS for SB 20, version D, from committee with individual recommendations and attached fiscal note(s). 1:35:39 PM CHAIR WILSON announced that seeing no objection, CSSB 20(HSS) moved from the Senate Health and Social Services Standing Committee.
Document Name | Date/Time | Subjects |
---|---|---|
SB 32 Legislation - Version J.pdf |
HHSS 4/13/2017 3:00:00 PM SHSS 2/10/2017 1:30:00 PM SHSS 2/15/2017 1:30:00 PM |
SB 32 |
SB 32 - Sectional Analysis.pdf |
HHSS 4/13/2017 3:00:00 PM SHSS 2/10/2017 1:30:00 PM |
SB 32 |
Fiscal Note DCCED CBPL.pdf |
HHSS 4/13/2017 3:00:00 PM SHSS 2/10/2017 1:30:00 PM |
SB 32 |
AK SB 32 Biosimilar Support Letter.pdf |
HHSS 4/13/2017 3:00:00 PM SHSS 2/10/2017 1:30:00 PM |
SB 32 |
ALF_AK SB 32__2 1 17 support.pdf |
HHSS 4/13/2017 3:00:00 PM SHSS 2/10/2017 1:30:00 PM |
SB 32 |
Alliance of Specialty Medicine AK SB 32 020317.pdf |
HHSS 4/13/2017 3:00:00 PM SHSS 2/10/2017 1:30:00 PM |
SB 32 |
GHLF AK SB 32 Comment Letter_Support 2-3-17.pdf |
HHSS 4/13/2017 3:00:00 PM SHSS 2/10/2017 1:30:00 PM |
SB 32 |
LADAAK support.pdf |
HHSS 4/13/2017 3:00:00 PM SHSS 2/10/2017 1:30:00 PM |
SB 32 |
NORD AK_SB 32_ltr.pdf |
HHSS 4/13/2017 3:00:00 PM SHSS 2/10/2017 1:30:00 PM |
SB 32 |
2-6-17 biosimilar AK support.pdf |
HHSS 4/13/2017 3:00:00 PM SHSS 2/10/2017 1:30:00 PM |
SB 32 |
NFK BioSimilars State Letter - Alaska 2.1.17.pdf |
HHSS 4/13/2017 3:00:00 PM SHSS 2/10/2017 1:30:00 PM |
SB 32 |
Alliance for Patient Access AfAP - SB32.pdf |
HHSS 4/13/2017 3:00:00 PM SHSS 2/10/2017 1:30:00 PM |
SB 32 |
Alliance for Safe Biologic Medicines AK-SB 32 -FNL.pdf |
HHSS 4/13/2017 3:00:00 PM SHSS 2/10/2017 1:30:00 PM |
SB 32 |
American Liver Foundation ALF_AK SB 32__2 1 17.pdf |
HHSS 4/13/2017 3:00:00 PM SHSS 2/10/2017 1:30:00 PM |
SB 32 |
SB 32 AARDA support.docx |
HHSS 4/13/2017 3:00:00 PM SHSS 2/10/2017 1:30:00 PM |
SB 32 |
Digestive Disease National Coalition Support for SB 32.pdf |
HHSS 4/13/2017 3:00:00 PM SHSS 2/10/2017 1:30:00 PM |
SB 32 |
Global Healthy Living Foundation GHLF AK SB 32 Comment Letter_Support 2-3-17.pdf |
HHSS 4/13/2017 3:00:00 PM SHSS 2/10/2017 1:30:00 PM |
SB 32 |
International Cancer Advocacy Network (ICAN) letter of support SB32.pdf |
HHSS 4/13/2017 3:00:00 PM SHSS 2/10/2017 1:30:00 PM |
SB 32 |
National Hispanic Medical Association (NHMA) _AK SB 32.pdf |
HHSS 4/13/2017 3:00:00 PM SHSS 2/10/2017 1:30:00 PM |
SB 32 |
Pharmaceutical Research and Manufacturers of America (PhRMA) Support SB32.PDF |
HHSS 4/13/2017 3:00:00 PM SHSS 2/10/2017 1:30:00 PM |
SB 32 |
Bios for Dr. Charles and Dr. Schneider.docx |
HHSS 4/13/2017 3:00:00 PM SHSS 2/10/2017 1:30:00 PM |
SB 32 |
SB 32 - BIO Support Letter 2-2-17 Biotechnology Innovation Organization.pdf |
HHSS 4/13/2017 3:00:00 PM SHSS 2/10/2017 1:30:00 PM |
SB 32 |
State Advocacy & Alliance Development, U.S. Pain Foundation - Alaska Senate Bill 32 Support.pdf |
SHSS 2/10/2017 1:30:00 PM |
SB 32 |
RetireSafe support SB32 2-6-17 biosimilar AK.pdf |
HHSS 4/13/2017 3:00:00 PM SHSS 2/10/2017 1:30:00 PM |
SB 32 |
US Pain.doc |
SHSS 2/10/2017 1:30:00 PM |
SB 32 |
1-12-17 Group letter.pdf |
HHSS 4/13/2017 3:00:00 PM SHSS 2/10/2017 1:30:00 PM |
SB 32 |
Potential Cost Savings of Biosimilar Drugs.pdf |
SHSS 2/10/2017 1:30:00 PM |
SB 32 |
SB 32 - 1 page handout explaining biosimilar legislation.docx |
HHSS 4/13/2017 3:00:00 PM SHSS 2/10/2017 1:30:00 PM |
SB 32 |
Alaska ACS CAN Biosimilars Fact Sheet 2017.pdf |
HHSS 4/13/2017 3:00:00 PM SHSS 2/10/2017 1:30:00 PM |
SB 32 |
Senate Bill 32 opposition AK Rheumatoloty Alliance.pdf |
HHSS 4/13/2017 3:00:00 PM SHSS 2/10/2017 1:30:00 PM |
SB 32 |
Alaska SB 32 - Merriman Comments 20170209.pdf |
HHSS 4/13/2017 3:00:00 PM SHSS 2/10/2017 1:30:00 PM |
SB 32 |
SupportLetter_Bio_SB32_psoriasis.docx |
HHSS 4/13/2017 3:00:00 PM SHSS 2/10/2017 1:30:00 PM |
SB 32 |